New vaccine to treat 15 types of cancer now available on NHS
A new jab which allows cancer patients to be treated with just one injection is set to be rolled out by the NHS for 15 different types of the disease.
Patients will be able to receive the immunotherapy in a vaccine, called nivolumab, in a treatment that will take just 15 minutes rather than spending an hour on an IV drip.
Around 1,200 patients a month will receive it for 15 different types of cancer, including skin, bladder and oesophageal cancer as England becomes the first country in Europe to offer it.
The drug is a monoclonal antibody that works by clinging to a protein called PD-1 on an immune cell called T-cell. It works by blocking cancer cells from switching off T-cells, allowing the immune system to seek out and destroy cancer cells.
NHS England said the jab, being rolled out to eligible patients next month, would save around 1,000 hours of treatment time for patients and clinicians every month.
Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This treatment is used for 15 different types of the disease, so it will free up thousands of valuable clinicians' time every year, allowing teams to treat even more patients and helping hospital capacity.
'And this is just the latest development in the NHS's ongoing commitment to provide patients with the latest cancer therapies and treatment options that truly transform lives.'
Minister for Public Health and Prevention, Ashley Dalton, said: "Britain is a hotbed of innovation, masterminding the newest tech and medical inventions to help people navigate illness. A new jab that fastens up cancer treatment is a prime example of this, so it's fantastic to see that cancer patients in England will be among the first in Europe to benefit.'
"With cancer medicines getting better all the time, this government will ensure that NHS patients are among the first to access the latest treatments and technology.'
And James Richardson, Clinical Pharmacist and National Specialty Adviser for Cancer Drugs, said: 'I am delighted that NHS patients across England will soon be able to benefit from this quicker-to-administer, effective treatment, that can be used to treat a range of cancer types, including skin cancer and solid tumours originating in the kidneys.
'This is a significant advancement in cancer treatment, with the potential to improve the lives of thousands of patients each month.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
AI foot scanner could keep people with heart failure out of hospital
An in-home foot scanner that uses artificial intelligence (AI) to recognise the warning signs of heart failure could help keep people with the condition out of hospital, according to researchers. The device, which is roughly the size of a smart speaker, operates in a similar way to facial recognition by taking and analysing almost 2,000 pictures a minute to calculate the level of fluid in the feet and ankles. This water retention, known as oedema, is one of the three major warning signs that heart failure is becoming severe and potentially life threatening. The AI scanner is able to trigger an alert to healthcare professionals so they can take action, such as increasing their patient's medication. The Foot Study, which is being presented at the British Cardiovascular Society annual conference in Manchester, suggests these alerts come 13 days before a person would end up in hospital. It involved 26 heart failure patients from five NHS trusts who were enrolled between 2020 and 2022. They were monitored using the AI device and were also asked to weigh themselves using Bluetooth-enabled scales. Seven instance of worsening heart failure was detected in six patients, while one death from the condition was recorded. Researchers found that, in patients enrolled in the study for at least two weeks before an alert was triggered, the average lead time before hospital admission was 13 days. The lead time averaged eight days when all five triggers picked up by the device were analysed. The study also found that monitoring using the scales failed to predict any heart failure-related hospital admissions. Researchers suggested this is because patients struggled to stick to tracking their weight, whereas the AI device did not require any action. Dr Philip Keeling, senior author of the study and a consultant cardiologist at Torbay and South Devon NHS Foundation Trust, said: 'Only about half of people admitted to hospital with heart failure currently get assigned an early review by a heart failure nurse who can check to see if they are suffering a harmful build-up of fluid because their heart is not working properly. 'Amid a shortage of heart failure nurses, a device like this can be like a virtual nurse, tracking people's health.' The device, developed by Cambridge-based start-up Heartfelt Technologies, is mounted to the wall and is typically installed at a patient's bedside. It uses AI technology to detect a person's foot and lower leg and track their position, so a camera can take 1,800 pictures a minute from multiple angles. These images reveal the volume of fluid in the foot and lower leg. It works without wifi, and only scans the legs to a height of 50cm from the floor. Heart failure is a long-term condition that means the heart is unable to pump blood around the body properly, usually because the heart has become too weak or stiff. Is it estimated that more than a million people are living with heart failure in the UK. The three main symptoms that indicate the condition is getting worse are increased breathlessness, weight gain and swelling in the legs or ankles. Dr Keeling added: 'Living with heart failure can be overwhelming, with all the medications, medical tests and appointments, and the requirement to monitor your own health. 'This scanner, once it is installed, just automatically keeps an eye on you and alerts the heart failure nurse, which is a huge relief.' At the end of the study, 18 of the 22 surviving patients kept the AI device. Reacting to the findings, Professor Bryan Williams, chief scientific and medical officer at the British Heart Foundation (BHF), said: 'This small study suggests a simple device could significantly improve outcomes for at-risk patients with heart failure by keeping them out of hospital. 'This study is a good example of how technology might aid earlier interventions and treatment, by allowing people to track a key sign of their heart health at home. 'Innovations with the potential to transform heart care in this way are a major part of the BHF's goal to save and improve lives of people living with cardiovascular disease.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
News Summary Up to six-fold increase in performance robustness with StepWave™ XR Ion Guide versus Xevo TQ Absolute.1 Uses up to 50% less power and gas, and occupies up to 50% less bench space than other products in its class.2 Takes the industry-leading sensitivity of Xevo TQ Absolute to new heights, including for PFAS detection and pharma quantitation applications. BALTIMORE and MILFORD, Mass., June 4, 2025 /PRNewswire/ -- 73rd ASMS Conference on Mass Spectrometry and Allied Topics – Waters Corporation (NYSE:WAT) today announced the launch of the Xevo™ TQ Absolute XR Mass Spectrometer, the Company's most sensitive, robust, and reliable benchtop tandem quadrupole. Notably, the product exceeds the performance capabilities of the Xevo TQ Absolute, which itself set the benchmark in the industry for tandem quadrupole sensitivity, particularly in areas such as pharmaceutical quantitation and PFAS detection. Tailored for high-throughput applications in pharmaceutical companies, contract testing organizations, and government laboratories, the new system is designed to deliver exceptional performance for the most sensitive trace-level analyses in complex matrices, while maximizing system uptime and efficiency. "Analytical laboratories are under pressure to adapt to the complex needs of pharmaceutical organizations, and meet the increasing demand for PFAS testing driven by a rapidly evolving regulatory landscape," said James Hallam, Vice President, Liquid Chromatography-Mass Spectrometry, Waters Corporation. "The Xevo TQ Absolute XR design delivers up to a six-fold increase in performance robustness with unmatched sensitivity and resilience to contamination, significantly reducing downtime and enhancing operational efficiency for our customers." Built on the trusted, intuitive design of the Xevo TQ Absolute Mass Spectrometer, the Xevo TQ Absolute XR Mass Spectrometer offers significant operational efficiencies. It uses up to 50% less power and nitrogen gas, produces 50% less heat than any other high-performing tandem or triple quadrupole on the market, and takes up to 50% less bench space, making it the ideal system for laboratories striving to reduce their environmental footprint without compromising throughput or performance. Within the Xevo TQ Absolute XR Mass Spectrometer, Waters introduces the StepWave XR Ion Guide, which incorporates sophisticated technology designed to minimize the risk of unplanned downtime, while preserving high sensitivity and precision for even the most complex sample types and fragile compounds. Through this innovation, customers are realizing a new benchmark of robustness across a wide range of applications, including PFAS, bioanalysis, and genotoxic impurity testing. "Our laboratory requires instrumentation that delivers high-quality, interruption-free results to our customers, helping them to bring safe and effective new drugs to market with confidence and speed," said Sally Hannam, Scientific Director, Synexa Life Sciences, a leading biomarker and bioanalytical services provider. "We are well in excess of 20,000 injections of crashed human plasma continuously analyzed on the Xevo TQ Absolute XR Mass Spectrometer combined with the ACQUITY™ Premier UPLC™ System and waters_connect™ Software, and our early experience is that it demonstrates new levels of reproducibility and accuracy, giving us ever more confidence as we are presented with increasingly challenging bioanalysis applications and new modalities." In addition, the design of the Xevo TQ Absolute XR Mass Spectrometer delivers industry-leading, out-of-the-box quantitation of negatively ionizing compounds, such as PFAS. Bioanalytical, food safety, and environmental testing laboratories will benefit from the high confidence results and operational efficiency gains that the Xevo TQ Absolute XR Mass Spectrometer delivers. The Xevo TQ Absolute XR Mass Spectrometer is available to order now. Additional Resources Product Page Waters, StepWave, ACQUITY, UPLC, waters_connect, and Xevo are trademarks of Waters Technologies Corporation. ABOUT: Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science. Contact: Molly GluckHead of External CommunicationsWaters Corporationmolly_gluck@ +1.617.833.8166 Application Note on Product Webpage. In a well-controlled experiment, performance was maintained for up to six times the duration on the Xevo TQ Absolute XR compared to the Xevo TQ Absolute; more than 12,000 samples of pesticides in fish feed matrix were analyzed. Based on a comparison of high-end tandem and triple quadrupole instruments available on the market. [Infographic] View original content: SOURCE Waters Corporation Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
AI foot scanner could keep people with heart failure out of hospital
An in-home foot scanner that uses artificial intelligence (AI) to recognise the warning signs of heart failure could help keep people with the condition out of hospital, according to researchers. The device, which is roughly the size of a smart speaker, operates in a similar way to facial recognition by taking and analysing almost 2,000 pictures a minute to calculate the level of fluid in the feet and ankles. This water retention, known as oedema, is one of the three major warning signs that heart failure is becoming severe and potentially life threatening. The AI scanner is able to trigger an alert to healthcare professionals so they can take action, such as increasing their patient's medication. The Foot Study, which is being presented at the British Cardiovascular Society annual conference in Manchester, suggests these alerts come 13 days before a person would end up in hospital. It involved 26 heart failure patients from five NHS trusts who were enrolled between 2020 and 2022. They were monitored using the AI device and were also asked to weigh themselves using Bluetooth-enabled scales. Seven instance of worsening heart failure was detected in six patients, while one death from the condition was recorded. Researchers found that, in patients enrolled in the study for at least two weeks before an alert was triggered, the average lead time before hospital admission was 13 days. The lead time averaged eight days when all five triggers picked up by the device were analysed. The study also found that monitoring using the scales failed to predict any heart failure-related hospital admissions. Researchers suggested this is because patients struggled to stick to tracking their weight, whereas the AI device did not require any action. Dr Philip Keeling, senior author of the study and a consultant cardiologist at Torbay and South Devon NHS Foundation Trust, said: 'Only about half of people admitted to hospital with heart failure currently get assigned an early review by a heart failure nurse who can check to see if they are suffering a harmful build-up of fluid because their heart is not working properly. 'Amid a shortage of heart failure nurses, a device like this can be like a virtual nurse, tracking people's health.' The device, developed by Cambridge-based start-up Heartfelt Technologies, is mounted to the wall and is typically installed at a patient's bedside. It uses AI technology to detect a person's foot and lower leg and track their position, so a camera can take 1,800 pictures a minute from multiple angles. These images reveal the volume of fluid in the foot and lower leg. It works without wifi, and only scans the legs to a height of 50cm from the floor. Heart failure is a long-term condition that means the heart is unable to pump blood around the body properly, usually because the heart has become too weak or stiff. Is it estimated that more than a million people are living with heart failure in the UK. The three main symptoms that indicate the condition is getting worse are increased breathlessness, weight gain and swelling in the legs or ankles. Dr Keeling added: 'Living with heart failure can be overwhelming, with all the medications, medical tests and appointments, and the requirement to monitor your own health. 'This scanner, once it is installed, just automatically keeps an eye on you and alerts the heart failure nurse, which is a huge relief.' At the end of the study, 18 of the 22 surviving patients kept the AI device. Reacting to the findings, Professor Bryan Williams, chief scientific and medical officer at the British Heart Foundation (BHF), said: 'This small study suggests a simple device could significantly improve outcomes for at-risk patients with heart failure by keeping them out of hospital. 'This study is a good example of how technology might aid earlier interventions and treatment, by allowing people to track a key sign of their heart health at home. 'Innovations with the potential to transform heart care in this way are a major part of the BHF's goal to save and improve lives of people living with cardiovascular disease.'
